Antibacterial activity in serum of the 3,5-diamino-piperidine translation inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 11, 2008, Pages 3369-3375

  Zhou, Yuefen ^a   Chow, Chun ^a   Murphy, Douglas E ^a   Sun, Zhongxiang ^a   Bertolini, Thomas ^a   Froelich, Jamie M ^a   Webber, Stephen E ^a   Hermann, Thomas ^a   Wall, Daniel ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

2 Deoxy streptamine; 3,5 Diamino piperidine; Aminoglycosides; Antibiotics; Decoding site; Ribosome; Translation inhibitors

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; N [4 (4,6 BIS(3,5 DIAMINO PIPERIDIN 1 YL) [1,3,5]TRIAZIN 2 YLAMINO) 2 HYDROXY PHENYL] 4 CHLORO BENZAMIDE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; CONTROLLED STUDY; DRUG POTENCY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA;

AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; COMBINATORIAL CHEMISTRY TECHNIQUES; DIAMINES; ESCHERICHIA COLI; MICE; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; PIPERIDINES; PROTEIN BIOSYNTHESIS; PSEUDOMONAS AERUGINOSA; STRUCTURE-ACTIVITY RELATIONSHIP;

BACTERIA (MICROORGANISMS); PSEUDOMONAS AERUGINOSA;

EID: 44149125075     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.04.023     Document Type: Article

References (15)

1. National Institute of Allergy and Infectious Disease Fact Sheet, April 2006.
2. Talbot G.H., Bradley J., Edwards J.E., Gilbert D., Scheld M., and Bartlett J.G. Clin. Infect. Dis. 42 (2006) 657
3. Zhou Y., Gregor V.E., Sun Z., Ayida B.K., Winters G.C., Murphy D., Simonsen K.B., Vourloumis D., Fish S., Froelich J.M., Wall D., and Hermann T. Antimicrob. Agents Chemother. 49 (2005) 4942
4. Zhou, Y.; Vourloumis, D.; Gregor, V. E.; Winters, G. C.; Hermann, T.; Ayida, B.; Sun, Z.; Murphy, D. E.; Simonsen, K. B. US patent application US7,223,759 B2, 2007. This patent describes the general syntheses for analogs containing triazine, pyridine, pyrimidine, benzene, and purine core structures.
5. There are two general methods (A & B in supplementary material) most frequently used for the synthesis of purine analogs. Only method A is described in Ref. 3b.
6. Pfister P., Hobbie S., Vicens Q., Böttger E.C., and Westhof E. ChemBioChem 4 (2003) 1078
7. Simonsen K.B., Ayida B.K., Vourloumis D., Winters G.C., Takahashi M., Shandrick S., Zhao Q., and Hermann T. ChemBioChem 4 (2003) 886
8. Vicens Q., and Westhof E. Biopolymers 70 (2003) 42
9. Busscher G.F., Rutjes F.P.J.T., and van Delft F.L. Chem. Rev. 105 (2005) 775
10. Zhou Y., Gregor V.E., Ayyida B.K., Winters G.C., Sun Z., Murphy D., Haley G., Bailey D., Froelich J.M., Fish S., Webber S.E., Hermann T., and Wall D. Bioorg. Med. Chem. Lett. 17 (2007) 1206
11. Zhou Y., Sun Z., Froelich J.M., Hermann T., and Wall D. Bioorg. Med. Chem. Lett. 16 (2006) 5451
12. Criag W.A., and Ebert S.C. Infect. Dis. Clin. North Am. 3 (1989) 407
13. Vourloumis D., Winters G.C., Takahashi M., Simonsen K.B., Ayida B.K., Shandrick S., Zhao Q., and Hermann T. ChemBioChem 4 (2003) 879
14. Barluenga S., Simonsen K.B., Littlefield E.S., Ayida B.K., Vourloumis D., Winters G.C., Takahashi M., Shandrick S., Zhao Q., Han Q., and Hermann T. Bioorg. Med. Chem. Lett. 14 (2004) 713
15. All the DAP derivatives described in this work are HCl salts.